Food, drug, insect sting allergy, and anaphylaxisIdentifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study
Section snippets
Study design
The LEAP screening study is a single-center, prospective, observational study that includes infants who underwent screening for an interventional trial termed the LEAP study (see the Methods section in this article's Online Repository at www.jacionline.org), which investigated the prevention of PA in high-risk children. Recruitment was targeted to families with young infants with eczema, egg allergy, or both. In this article the term eczema is identical to the term atopic dermatitis.
Demographics of screened subjects
Infants were recruited for the LEAP study from November 2006 to May 2009. A total of 2829 potential participants contacted the clinical trials unit, and 899 underwent screening (see Fig 1 for details). Of these, 65 were not considered further because the appropriate LEAP stratum was closed or they withdrew consent or for other reasons. The remaining 834 subjects comprise the LEAP screening study cohort. For these, mean age was 7.8 months (range, 4-10 months), with slightly more male subjects
Discussion
An intervention needs to be directed at a population that is at high risk of PA, without having already had allergy, to successfully prevent PA. The study definition of “high risk” included egg allergy, severe eczema, or both. Our analysis demonstrates that the LEAP study recruitment strategy was able to identify an appropriate atopic population of young infants because the majority of enrolled infants had detectable peanut-specific IgE levels at screening. Our data demonstrate that the
References (33)
- et al.
Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy
J Allergy Clin Immunol
(2008) - et al.
Rising prevalence of allergy to peanut in children: data from 2 sequential cohorts
J Allergy Clin Immunol
(2002) - et al.
US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up
J Allergy Clin Immunol
(2010) - et al.
Fatalities due to anaphylactic reactions to foods
J Allergy Clin Immunol
(2001) - et al.
The natural progression of peanut allergy: resolution and the possibility of recurrence
J Allergy Clin Immunol
(2003) - et al.
Maternal consumption of peanut during pregnancy is associated with peanut sensitization in atopic infants
J Allergy Clin Immunol
(2010) - et al.
The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance
J Allergy Clin Immunol
(1995) - et al.
Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays
J Allergy Clin Immunol
(2002) - et al.
Diagnosing peanut allergy with skin prick and specific IgE testing
J Allergy Clin Immunol
(2005) - et al.
Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents
J Allergy Clin Immunol
(1997)
Utility of food-specific IgE concentrations in predicting symptomatic food allergy
J Allergy Clin Immunol
Increasing the accuracy of peanut allergy diagnosis by using Ara h 2
J Allergy Clin Immunol
National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006
J Allergy Clin Immunol
Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK
Allergy
Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants
J Allergy Clin Immunol
Race, ancestry, and development of food-allergen sensitization in early childhood
Pediatrics
Cited by (214)
Overview of the Essential Knowledge for Clinical Practice in Allergy and Immunology
2023, Physician Assistant ClinicsThe protective effect of moderate maternal peanut consumption on peanut sensitization and allergy
2023, Annals of Allergy, Asthma and ImmunologyFood Allergy
2023, Primary Care - Clinics in Office PracticeEarly peanut introduction: To test or not to test?
2023, Annals of Allergy, Asthma and ImmunologyDefining the window of opportunity and target populations to prevent peanut allergy
2023, Journal of Allergy and Clinical ImmunologyPrenatal and perinatal risk factors of food allergy in Taiwanese young children
2022, World Allergy Organization Journal
This study was supported by the Immune Tolerance Network (funded by the National Institute of Allergy and Infectious Diseases); the Food Allergy Initiative, New York, NY; the Food Standards Agency, United Kingdom; the Food Allergy and Anaphylaxis Network, Fairfax, Va; the MRC & Asthma UK Centre; and the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The clinical trials unit is supported by the National Peanut Board, Atlanta, Ga.
Disclosure of potential conflict of interest: G. Roberts has received research support from the Immune Tolerance Network (ITN). P. H. Sayre has received travel support from the National Institute of Allergy and Infectious Diseases (NIAID). H. T. Bahnson and H. Mitchell have received research support from the National Institutes of Health. S. Radulovic has received research support from the ITN/NIAID, the Food Allergy Initiative, and the National Peanut Board and has received travel support from Stallergenes and the Allergy Academy. S. Chan has received research support from the ITN/NIAID, the Food Allergy Initiative, the National Peanut Board, the Food Standards Agency, the Food Allergy & Anaphylaxis Network, MRC & Asthma UK Centre, and the Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre award to the Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. V. Turcanu has received research support from the ITN. G. Lack has received research support from the ITN/NIAID, the Food Allergy Initiative, the National Peanut Board, the Food Standards Agency, the Food Allergy and Anaphylaxis Network, MRC Asthma UK Centre, and the Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre award to the Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust; is on the DBV Technologies advisory board; is a voluntary scientific advisor for the Anaphylaxis Campaign and the National Peanut Board; has received lecture fees from Sodilac, Novartis, Nestlé Nutrition, GlaxoSmithKline, and the Serono Symposia International Foundation; and has stock/stock options in DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.